Quadrant Capital Group LLC Dyne Therapeutics, Inc. Transaction History
Quadrant Capital Group LLC
- $1.43 Billion
- Q4 2024
A detailed history of Quadrant Capital Group LLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 231 shares of DYN stock, worth $1,725. This represents 0.0% of its overall portfolio holdings.
Number of Shares
231
Previous 231
-0.0%
Holding current value
$1,725
Previous $8,000
37.5%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding DYN
# of Institutions
211Shares Held
103MCall Options Held
135KPut Options Held
435K-
Atlas Venture Life Science Advisors, LLC8.02MShares$59.9 Million31.16% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$55.2 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.38MShares$55.1 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.7MShares$50.1 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.38MShares$47.7 Million2.43% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $387M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...